RhumbLine Advisers’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $208K | Buy |
44,165
+7,920
| +22% | +$37.2K | ﹤0.01% | 3212 |
|
|
2025
Q1 | $132K | Sell |
36,245
-139
| -0.4% | -$507 | ﹤0.01% | 3295 |
|
|
2024
Q4 | $172K | Buy |
36,384
+3,049
| +9% | +$14.4K | ﹤0.01% | 3269 |
|
|
2024
Q3 | $310K | Sell |
33,335
-2,575
| -7% | -$24K | ﹤0.01% | 3006 |
|
|
2024
Q2 | $206K | Buy |
35,910
+9,171
| +34% | +$52.7K | ﹤0.01% | 3205 |
|
|
2024
Q1 | $179K | Buy |
26,739
+778
| +3% | +$5.22K | ﹤0.01% | 3229 |
|
|
2023
Q4 | $167K | Sell |
25,961
-465
| -2% | -$3K | ﹤0.01% | 3270 |
|
|
2023
Q3 | $132K | Buy |
26,426
+999
| +4% | +$5K | ﹤0.01% | 3365 |
|
|
2023
Q2 | $179K | Buy |
25,427
+113
| +0.4% | +$796 | ﹤0.01% | 3291 |
|
|
2023
Q1 | $157K | Sell |
25,314
-437
| -2% | -$2.71K | ﹤0.01% | 2794 |
|
|
2022
Q4 | $164K | Buy |
25,751
+973
| +4% | +$6.2K | ﹤0.01% | 2834 |
|
|
2022
Q3 | $213K | Buy |
24,778
+1,701
| +7% | +$14.6K | ﹤0.01% | 2872 |
|
|
2022
Q2 | $314K | Buy |
23,077
+401
| +2% | +$5.46K | ﹤0.01% | 2728 |
|
|
2022
Q1 | $345K | Buy |
22,676
+3,223
| +17% | +$49K | ﹤0.01% | 2593 |
|
|
2021
Q4 | $445K | Buy |
19,453
+979
| +5% | +$22.4K | ﹤0.01% | 2558 |
|
|
2021
Q3 | $257K | Buy |
18,474
+2,815
| +18% | +$39.2K | ﹤0.01% | 2828 |
|
|
2021
Q2 | $167K | Buy |
+15,659
| New | +$167K | ﹤0.01% | 2936 |
|